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Subcapsular  liver  hematoma  as  a  complication  of  an
atypical hemolytic  uremic  syndrome
Hematoma  subcapsular  hepático  como  complicación  de  síndrome
hemolítico  urémico  atípico
Dear Editor:
Atypical hemolytic uremic syndrome (aHUS) is a rare,
life-threatening systemic inﬂammatory disease that pre-
followed by subsequent doses of 1200 mg every 2 weeks since
the 5th week. Thereupon, platelet count increased and hemo
dialysis was suspended on the ICU D35. She was transferredsents classically with microangiopathic hemolytic anemia,
thrombocytopenia and acute kidney injury.1 Extra renal mani-
festations are observed in 20% of patients.2
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to the Nephrology ward on the ICU D42 and was discharged
home three weeks later. The ﬁnal genetic workup was availa-
ble only after discharge and detected a complement factor H
haplotype H3 (−332T, c.184G, c.1204T, c.2016G, and c.2808T).
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-A 42-year-old woman  with unremarkable past medica
history presented in our hospital reporting a 6-day histor
of headache, nausea and vomiting. Physical examination
showed hypertension (220/120 mmHg), cutaneous pallor an
moderate lower limbs edema. Laboratory results reveale
anemia (hemoglobin 8.4 g/dl), thrombocytopenia (76,000/l
severe azotemia (urea 16.9 mmol/l, creatinine 448.8 mol/l
schistocytosis, a negative Coombs test, low blood haptoglo
bin (<0.07 g/L) and high lactate dehydrogenase levels (1234 U/l
Renal ultrasonography was normal.
Blood pressure was hardly controlled with oral medication
A diagnosis of acute thrombotic microangiopathy (ATM) wa
made and daily plasma exchange (PEX) was started.
Investigations for secondary causes of ATM (pregnancy
auto-immune disease, malignancy, drug-induced), infection
induced HUS and thrombotic thrombocytopenic purpura wer
normal. A presumptive diagnosis of aHUS was made an
the administrative process of Eculizumab acquisition was ini
tiated.
On the 15th day of admission (D15), hemodialysis was star
ted due to progressive renal failure. All attempts to stop PEX
resulted in increased hemolytic activity, forcing to maintain 
sessions a week.
On the D72, after performing 44 PEX sessions, we wer
still waiting for Eculizumab acquisition. Attending to clini
cal and analytical stability (Fig. 1), the patient was discharge
home to continue hemodialysis and PEX three times a wee
as an outpatient. Four days after discharge, she was admit
ted in the emergency room with a 12-hour history of sever
right upper quadrant pain and vomiting without history o
trauma. Laboratory results revealed stabilized hemoglobin
(11.1 g/dl) and both normal platelet count (157,000/mm3) an
coagulation tests. Abdominal ultrasonography and Compute
Tomography scan showed a large subcapsular liver hematoma
(SLH) (Fig. 2).
She was transferred to the Intensive Care Unit (ICU).
Attending to hemodynamic stability, a conservative approach
was attempted. PEX was suspended to prevent increased
hepatic bleeding related with heparin systemic anticoa-
gulation. Ultrasonography follow-up examinations revealed
almost unchanged size of hematoma.
Eculizumab was started on the 10th day of admission in
the ICU (ICU D10) at a dose of 900 mg per week for 4 weeks,Currently, 8 months after eculizumab initiation, hema
tologic remission persists, renal function remains stable
(ﬁgure 1) and last ultrasonography control showed a signi
ﬁcant decrease in the size of hematoma – 3.94 cm × 1.3 cm
Alternate-week eculizumab infusions are still being conti
nued.
Discussion: Complement system dysregulation in aHUS
induces thickening and inﬂammation of vascular wall, wide
ning of subendothelial space and microvascular thrombosis.
Renal microvasculature is predominantly affected but extrare
nal ischemic events, mainly involving central nervous system
were also reported.2 Few hemorrhagic events were also repor
ted in patients with infection-induced HUS and in secondary
causes of ATM.3–5 Only three hemorrhagic events, affecting
pulmonary vasculature, were previously reported in aHUS
patients.6–8
SLH is a rare event that is mainly related with pregnancy
induced hypertension (preeclampsia and HELLP syndrome
and primary or metastatic liver tumors.9 Since HELLP syn
drome is an ATM like aHUS,1 we speculate that SLH
pathogenesis might be similar in both diseases. In HELLP syn
drome, SLH is thought to be a consequence of hepatic blood
ﬂow obstruction due to ﬁbrin deposits within hepatic
sinusoids, resulting in periportal necrosis and intrahepatic
hemorrhage.10 Likewise, we believe vascular rupture in aHUS
might result from hepatic blood ﬂow obstruction secondary to
complement-induced microvascular thrombosis. Other pos
sible contributors for bleeding diathesis in our patient were
uremic platelet dysfunction, difﬁcult-to-control hypertension
and heparinization during dialysis and PEX. It is importan
to note that at the time of SLH diagnosis platelet count and
coagulation tests were normal.
There is currently no documentation on the role of eculi
zumab to rescue aHUS-related hemorrhagic events since none
of the previously reported cases used it. However, we  believe
that the blockade of vascular injury achieved by eculizumab
might have had some beneﬁcial effect.
Current treatment of aHUS relies on early onset of ecu-
lizumab based solely on clinical and laboratorial data.1 The
decision to start eculizumab in our patient was made one week
after presentation but the high cost of Eculizumab limited
its immediate availability and forced us to rely on extensive
and ineffective PEX while waiting for the immunoglobulin.
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g. 1 – Clinical course: laboratory data and treatment. Blood transfusions were done when hemoglobin got around 8 g/dl.
lasma exchange consisted of one volume exchange with fresh frozen plasma. It was started on the second day of
dmission and maintained until there was no evidence of hemolytic activity. Attempts at weaning plasma exchange were
nsuccessful due to increased hemolytic activity, forcing us to maintain 3 sessions a week until the diagnosis of the
bcapsular liver hematoma. We performed a total of 44 plasma exchange sessions. Hemodialysis was commenced on the
5th day of admission to manage her renal failure. Eculizumab was administered at a dose of 900 mg  per week for 4 weeks,
arted on the 85th day after admission, followed by a dosage of 1200 mg  1 week later and then a maintenance dose of
200 mg  every 2 weeks. During the ﬁrst days of eculizumab usage, we  could not use hemoglobin neither lactate
ehydrogenase to monitor hematologic response attending to the presence of the subcapsular liver hematoma that would
istort their interpretation. Hemodialysis was stopped 26 days after the ﬁrst infusion of eculizumab. Eculizumab is still
eing continued on the maintenance schedule of 1200 mg  every 2
13–618 U/l; platelet count – 150–400 × 103/mm3; hemoglobin – 12 weeks. Reference range values: lactate dehydrogenase –
–16 g/dl; plasma creatinine – 46–92 mol/l.
n e f r o l o g i a 2 0 1 5;3  5(3):328–339 339
mm/Abdomen
A B
Fig. 2 – Abdominal computed tomography (A) and liver ultrasound (B) revealing a large subcapsular liver hematoma
(13.8 cm × 3.9 cm)  (arrows) causing compression of the underlying liver parenchyma. No source for the hemorrhage was
evident.
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tConversely, Eculizumab initiation allowed immediate hema
tologic complete remission and induced remarkable rena
recovery with discontinuation of dialysis after 3 months o
replacement therapy.
In summary, our case highlights the ﬁrst report of a SLH
complicating an aHUS and reinforces the importance of an
earlier intervention with Eculizumab to improve clinical out
comes and to prevent the onset of severe complications.
Conﬂict  of  interest
The authors declare that they have no conﬂicts of interes
related to the contents of this article.
b  i  b  l  i  o  g  r  a  f  í  a1. Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa M,
Grinyó JM, et al. Actualización en síndrome hemolítico
urémico atípico: diagnóstico y tratamiento. Documento de
consenso. Nefrologia. 2013;33:27–45.
2. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic
syndrome. Orphanet J Rare Dis. 2011;6:60.
3. Torra R, Poch E, Torras A, Bombí JA, Revert L. Pulmonary
hemorrhage as a clinical manifestation of hemolytic-uraemic
syndrome associated with mitomycin C therapy.
Chemotherapy. 1993;39:453–6.
4. Au WY, Tang SC, Chan KW, Wong KK, Ooi CG. Pulmonary
renal syndrome and thrombotic thrombocytopenic purpura
in a patient with giant cavernous hemangioma of the leg.
Arch Intern Med. 2002;162:221–2.
5. Sakallioglu O, Gok F, Kalman S, Gokcay E. Renal subcapsular
hematoma in hemolytic uremic syndrome. Indian J Nephrol.
2005;15 Suppl.:S37–8.
6. Derebail VK, Parikh P, Jennette JC, Kshirsagar AV. A rare cause
of the pulmonary-renal syndrome: a case of atypicalhaemolytic-uraemic syndrome complicated by pulmonary
haemorrhage. NDT Plus. 2008;1:417–9.
7. Hong JY, Jung JY, Kang YA, Bae YS, Kim YS, Kim SK, et al.
Delayed hemolytic uremic syndrome presenting as diffuse
alveolar hemorrhage. Korean J Crit Care Med. 2014;29:
43–7.
8. Rhee H, Song SH, Lee YJ, Choi HJ, Ahn JH, Seong EY, et al.
Pandemic H1N1 inﬂuenza A viral infection complicated by
atypical hemolytic uremic syndrome and diffuse alveolar
hemorrhage. Clin Exp Nephrol. 2011;15:948–52.
9. Klein K, Shapiro AM. Spontaneous hepatic rupture with
intraperitoneal hemorrhage without underlying etiology: a
report of two cases. ISRN Surg. 2011;2011:610747.
10. Cernea D, Dragoescu A, Novac M. HELLP syndrome
complicated with postpartum subcapsular ruptured liver
hematoma and purtscher-like retinopathy. Case Rep Obstet
Gynecol. 2012;2012:856135.
Emanuel Ferreiraa,∗, Nuno Oliveiraa, Maria Marquesa,
Helena Pintoa, Ana Santosa, Armando Carreiraa,
Mário Camposb
a Servicio de Nefrología, Centro Hospitalar e Universitário de
Coimbra – Hospital Geral, Coimbra, Portugal
b Servicio de Nefrología, Centro Hospitalar e Universitário de
Coimbra – Hospitais da Universidade de Coimbra, Coimbra,
Portugal
∗ Corresponding author.
E-mail address: emanuelfeferreira@gmail.com
(E. Ferreira).
0211-6995/© 2015 The Authors. Published by Elsevier
España, S.L.U. on behalf of Sociedad Española de Nefrología.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.nefro.2015.03.003
